Jul 25, 2024
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
Read more
Jul 24, 2024
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
Read more
Jul 17, 2024
Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
Read more
Jun 13, 2024
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Read more
Jun 12, 2024
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Read more
Jun 12, 2024
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
Read more
Jun 11, 2024
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
Read more
Jun 04, 2024
Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
Read more
Displaying 1 - 10 of 34